H.C. Wainwright Maintains BioXcel Therapeutics(BTAI.US) With Buy Rating, Cuts Target Price to $5
BioXcel Therapeutics Is Maintained at Buy by HC Wainwright & Co.
BioXcel Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Bioxcel Therapeutics (BTAI) and Arcutis Biotherapeutics (ARQT)
Mizuho Securities Maintains BioXcel Therapeutics(BTAI.US) With Hold Rating, Announces Target Price $1
HC Wainwright & Co. Reiterates Buy on BioXcel Therapeutics, Maintains $7 Price Target
BioXcel Therapeutics Analyst Ratings
Bioxcel Therapeutics Earns Buy Rating on Promising Clinical Trials and Market Potential
Bioxcel Therapeutics (BTAI) Receives a Hold From Mizuho Securities
HC Wainwright & Co. Maintains Buy on BioXcel Therapeutics, Lowers Price Target to $7
BioXcel Therapeutics Analyst Ratings
Buy Rating Maintained for Bioxcel Therapeutics Amid Positive Performance and Growth Prospects
Canaccord Genuity Maintains Buy on BioXcel Therapeutics, Maintains $7 Price Target
BioXcel Therapeutics Analyst Ratings
Analysts' Opinions Are Mixed on These Healthcare Stocks: Teleflex (TFX), Bioxcel Therapeutics (BTAI) and Prothena (PRTA)
Hold Rating on Bioxcel Therapeutics Amid Growth Potential and Financial Uncertainties
HC Wainwright & Co. : The BioXcel Therapeutics (BTAI.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $10.00.
BioXcel Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on BioXcel Therapeutics, Maintains $10 Price Target
Bullish Outlook: Bioxcel Therapeutics' Revenue Surge and Promising Clinical Trials Fuel Buy Rating